- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Ligand id: 5677
View more information in the IUPHAR Pharmacology Education Project: tofacitinib
Molecular properties generated using the CDK
|Like many first generation kinase inhibitors tofacitinib exhibits a high degree of broad kinome selectivity but is in reality a pan-JAK-inhibitor. Additional kinases inhibited by tofacitinib in biochemical and cellular assays are described in . Tofacitinib is also reported to exhibit immunosuppressive activity which prevents organ rejection in mice and primates .
Despite clinical efficacy in ulcerative colitis, tofacitinib did not show significant efficacy as an induction and maintenance therapy over placebo, in Crohn's disease patients (as evaluated in Phase 2 studies NCT01393626 and NCT01393899) .
|Selectivity at enzymes|
|Key to terms and symbols||Click column headers to sort|